iBio, Inc. Announces Rights Grant for Anthrax-Plague Combination Vaccine To Fraunhofer USA Center for Molecular Biotechnology
Published: Apr 07, 2010
NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (OTCBB: IBPM) confirmed today the grant of rights to use iBio’s proprietary technology, the iBioLaunch™ platform, in support of a $5.3 million government-funded project for the development of a single vaccine to protect against both anthrax and plague. The project will be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology.